On April 27, 2026 Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, reported the acceptance of an Australian patent covering its core payload technology, and further expanding protection of its proprietary ADC platform.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The accepted patent (Application No. 2024201765), titled "Thailanstatin Analogs," includes composition-of-matter claims covering proprietary analogs of Thailanstatin designed for use as cytotoxic ADC therapeutics. This patent contains broad claims covering the use of these proprietary splicing payloads with state-of-the-art ADC linkers and may be used to target different proteins on the cancer cell.

Akari’s growing pipeline of novel ADCs including AKTX-101 (targeting TROP2 directed) and AKTX-102 (targeting CEACAM5) all use the PH1 payload that is built around this novel IP. Targeting RNA splicing biology has the potential to be a highly effective and differentiated strategy to attack cancer tumors in multiple ways by eliminating vital proteins needed for cancer cell survival, as well as uniquely activating the immune system to drive durable efficacy.

"This patent acceptance strengthens the foundation of our proprietary payload platform and reinforces our ability to build a differentiated ADC pipeline," said Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics. "Our RNA splicing payload enable us to build a novel class of ADC therapeutics that have the potential to disrupt the current ADC category, and we believe expanding broad composition-of-matter protection globally is critical to unlocking multiple ADCs across tumor types and major markets around the world. This patent grant continues to increase the total value of
Akari’s novel ADC technology, while enabling us to advance the development of cancer therapies for patients across the world while protecting our intellectual property."

This Australian patent approval builds on Akari’s expanding global intellectual property portfolio, which includes issued patents in the United States, China, India, Japan, Israel, and Mexico, further strengthening protection of its proprietary PH1 payload platform and reinforcing the Company’s strategy to establish broad, global composition-of-matter coverage.

Akari’s lead program, AKTX-101, a TROP2-targeting ADC powered by its proprietary PH1 payload, is currently in IND-enabling studies with a targeted Phase 1 first-in-human clinical trial expected in late 2026/ early 2027. This enables Akari to continue to advance its novel ADC into a rapidly evolving TROP2 ADC class expected to reach ~$12B by 20331.

This patent approval further strengthens Akari’s intellectual property across payload chemistry, ADC architecture, and therapeutic applications, supporting the Company’s strategy to advance a durable and differentiated platform for next-generation ADC development.

(Press release, Akari Therapeutics, APR 27, 2026, View Source [SID1234664787])